Abstract
Due to their unique physical and chemical properties, the potential application of nanomaterials in medicine is partic¬ularly attractive. Despite the many advantages that nanomaterials can offer as diagnostic and therapeutic tools, their transition from the bench to clinical practice is extremely challenging. One of the many barriers that nanomedicines may encounter is their toxicological effect. In fact, the development of novel nanomaterials / nanoparticles must pro¬ceed always in tandem with the assessment of any potential toxicological effects associated to them. Once nano¬materials reach the systemic circulation, they interact with endothelial cells, plasma proteins, and other blood compo¬nents. There is no doubt that the study of nanomaterials-blood interactions is crucial to warrant the biocompatibility of nanomaterials developed for human use.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Review of Clinical Pharmacology and Pharmacokinetics - International Edition
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
